Brian Piekos's most recent trade in KalVista Pharmaceuticals Inc was a trade of 5,000 Restricted Stock Unit done . Disclosure was reported to the exchange on Feb. 21, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| KalVista Pharma Inc | Brian Piekos | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2026 | 5,000 | 60,000 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Brian Piekos | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2026 | 5,000 | 15,529 (0%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Brian Piekos | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 15.57 per share. | 21 Feb 2026 | 1,767 | 13,762 (0%) | 0% | 15.6 | 27,507 | Common Stock |
| KalVista Pharma Inc | Brian Piekos | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2026 | 100,000 | 100,000 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Brian Piekos | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2025 | 15,000 | 65,000 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Brian Piekos | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2025 | 15,000 | 15,000 (0%) | 0% | - | Common Stock | |
| KalVista Pharma Inc | Brian Piekos | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 13.45 per share. | 21 Nov 2025 | 4,471 | 10,529 (0%) | 0% | 13.5 | 60,139 | Common Stock |
| KalVista Pharma Inc | Brian Piekos | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 80,000 | 80,000 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Brian Piekos | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2024 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Elicio Therapeutics Inc | Piekos Brian | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 43,225 | 43,225 | - | - | Stock Option (right to buy) | |
| Elicio Therapeutics Inc | Brian Piekos | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 75,484 | 75,484 | - | - | Stock Option (right to buy) | |
| Disc Medicine Inc | Brian Piekos | CFO | Grant, award, or other acquisition of securities at price $ 1.09 per share. | 31 May 2022 | 9,960 | 17,615 | - | 1.1 | 10,856 | Common Stock |
| Disc Medicine Inc | Brian Piekos | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2022 | 280,876 | 280,876 | - | - | Restricted Stock Units | |
| Disc Medicine Inc | Brian Piekos | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Oct 2021 | 90,720 | 90,720 | - | - | Restricted Stock Units | |
| Disc Medicine Inc | Brian Piekos | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 9.46 per share. | 14 May 2021 | 7,655 | 7,655 | - | 9.5 | 72,432 | Common Stock |
| Disc Medicine Inc | Brian Piekos | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2021 | 377,734 | 377,734 | - | - | Stock Option (Right to Buy) |